TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03193580

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal High Definition tDCS
Description: HD-tDCS will be applied for 20 minutes at 1milliamp while participants are performing a fine motor task. The current will be set at 1milliamp, stimulation will be ramped up over 30 seconds and ramped down over 30 seconds.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: tDCS will be applied for 1 minutes at 1milliamp while participants are performing a fine motor task. The current will be set at 1milliamp, stimulation will be ramped up over 30 seconds and ramped down over 30 seconds.
Study: NCT00833703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Form: reconstituted solution using Clopidogrel powder~Route: oral or enteric~Frequency: once daily~Dose: daily dose adjusted for weight

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Form: reconstituted solution using matching placebo powder~Route: oral or enteric~Frequency: once daily~Dose: daily dose adjusted for weight
Study: NCT00363298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dextro-amphetamine
Description: dextro-amphetamine dosage form: 15 mg capsules, in Bottles A and B. Dosage: One capsule from Bottle A and one capsule from bottle B each morning. Frequency: once daily. Duration: 5 weeks.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham Comparison
Description: caffeine dosage form: capsules identical to those in dextro-amphetamine arm, but containing 200 mg caffeine in Bottle A and 100 mg caffeine in Bottle B. Frequency: once daily. Duration: 5 weeks
Study: NCT00663078

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief CBT Group therapy
Description: CBT based therapy also expert patient programme

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief CBT Group therapy
Description: CBT based therapy also expert patient programme
Study: NCT02649309

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RIPre
Description: Preconditioning 200 mmHg x 5 minutes before procedure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RIPre
Description: Preconditioning 200 mmHg x 5 minutes before procedure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sham-Pre
Description: Sham 10 mmHg x 5 minutes before procedure

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham-Pre
Description: Sham 10 mmHg x 5 minutes before procedure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RIPost
Description: Postconditioning 200 mmHg x 5 minutes after procedure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RIPost
Description: Postconditioning 200 mmHg x 5 minutes after procedure
Study: NCT01858571

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Low dose chemotherapy
Description: Metronomic chemotherapy schedule : Alternating cycles of Cycle A and B (Each cycle includes 3 weeks of drug administration) with each drug rounded off to the nearest tablet/capsule size.~Cycle A~* Daily oral Thalidomide (at 3mg/kg)~* Daily oral Celecoxib (100 mg BID for patients \< 20 kg, 200 mg BID for patients 20-50 kg, and 400 mg BID for patients \> 50 kg)~* Daily oral Etoposide (50 mg/m2/d)~Cycle B~* Daily oral Thalidomide (at 3mg/kg)~* Daily oral Celecoxib (100 mg BID for patients \< 20 kg, 200 mg BID for patients 20-50 kg, and 400 mg BID for patients \> 50 kg)~* Daily oral Cyclophosphamide (2.5 mg/kg/d to a maximum of 100 mg/d) every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose chemotherapy
Description: Metronomic chemotherapy schedule : Alternating cycles of Cycle A and B (Each cycle includes 3 weeks of drug administration) with each drug rounded off to the nearest tablet/capsule size.~Cycle A~* Daily oral Thalidomide (at 3mg/kg)~* Daily oral Celecoxib (100 mg BID for patients \< 20 kg, 200 mg BID for patients 20-50 kg, and 400 mg BID for patients \> 50 kg)~* Daily oral Etoposide (50 mg/m2/d)~Cycle B~* Daily oral Thalidomide (at 3mg/kg)~* Daily oral Celecoxib (100 mg BID for patients \< 20 kg, 200 mg BID for patients 20-50 kg, and 400 mg BID for patients \> 50 kg)~* Daily oral Cyclophosphamide (2.5 mg/kg/d to a maximum of 100 mg/d) every 21 days
Study: NCT00776282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: loratadine 10 mg orally disintegrating

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: loratadine 10 mg orally disintegrating
Study: NCT02649309

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sham-Post
Description: Sham 10 mmHg x 5 minutes after procedure

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham-Post
Description: Sham 10 mmHg x 5 minutes after procedure
Study: NCT03033784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 8 International Units (IU) of Oxytocin
Description: Participants will receive one dose of intranasal oxytocin at a dose of 8IU.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 24IU of Oxytocin
Description: Participants will receive one dose of intranasal oxytocin at a dose of 24IU.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 48IU of Oxytocin
Description: Participants will receive one dose of intranasal oxytocin at a dose of 48IU.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive an intranasal placebo to match the oxytocin doses.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive an intranasal placebo to match the oxytocin doses.
Study: NCT03484923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDR001
Description: 400 mg of PDR001 administered every 4 weeks intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDR001
Description: 400 mg of PDR001 administered every 4 weeks intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDR001
Description: 400 mg of PDR001 administered every 4 weeks intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDR001
Description: 400 mg of PDR001 administered every 4 weeks intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAG525
Description: 600 mg of LAG525 administered every 4 weeks intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAG525
Description: 600 mg of LAG525 administered every 4 weeks intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INC280
Description: 400 mg of INC280 administered twice daily orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACZ885
Description: 200 mg of ACZ885 administered every 4 weeks subcutaneosuly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEE011
Description: 600 mg of LEE011 orally taken once daily on Days 1-21 of a 28-day cycle
Study: NCT02458079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxiphylline
Study: NCT01573429

Intervention type: OTHER
Group type: OTHER
Intervention: deuterated-Bisphenol A (d-BPA)
Description: The primary endpoints are key pharmacokinetic measurements of d-BPA and d-BPA conjugates in blood and urine over 6 days after a single dose of oral and/or ethanol solution dermal application and/or a carboxymethylcellulose suspension dermal application of a dose of 100 micro g/kg bw of d-BPA.

Intervention type: OTHER
Group type: OTHER
Intervention: deuterated-Bisphenol A (d-BPA)
Description: The primary endpoints are key pharmacokinetic measurements of d-BPA and d-BPA conjugates in blood and urine over 6 days after a single dose of oral and/or ethanol solution dermal application and/or a carboxymethylcellulose suspension dermal application of a dose of 100 micro g/kg bw of d-BPA.
Study: NCT02458079

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stool microbiota transplantation
Study: NCT02053272

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GWP42004
Description: The total dose administered within any 24-hour interval will be two capsules (typically 12 hours apart).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GWP42004
Description: The total dose administered within any 24-hour interval will be two capsules (typically 12 hours apart).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GWP42004
Description: The total dose administered within any 24-hour interval will be two capsules (typically 12 hours apart).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The total dose administered within any 24-hour interval will be two capsules (typically 12 hours apart).
Study: NCT02476981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Patients given remifentanil received continuous infusion of the drug at 1-5 µg/kg/h

Intervention type: DRUG
Group type: OTHER
Intervention: Remifentanil
Description: Patients given remifentanil received continuous infusion of the drug at 1-5 µg/kg/h
Study: NCT01573429

Intervention type: OTHER
Group type: OTHER
Intervention: deuterated-Bisphenol A (d-BPA)
Description: The primary endpoints are key pharmacokinetic measurements of d-BPA and d-BPA conjugates in blood and urine over 6 days after a single dose of oral and/or ethanol solution dermal application and/or a carboxymethylcellulose suspension dermal application of a dose of 100 micro g/kg bw of d-BPA.
Study: NCT02476981

Intervention type: DRUG
Group type: OTHER
Intervention: Remifentanil
Description: Patients given remifentanil received continuous infusion of the drug at 1-5 µg/kg/h

Intervention type: DRUG
Group type: OTHER
Intervention: Remifentanil
Description: Patients given remifentanil received continuous infusion of the drug at 1-5 µg/kg/h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Patients receiving dexmedetomidine were given that drug at 0.3-0.4 µg/kg over 10 min, followed by continuous infusion of 0.2 1 µg/kg/h

Intervention type: DRUG
Group type: OTHER
Intervention: Dexmedetomidine
Description: Patients receiving dexmedetomidine were given that drug at 0.3-0.4 µg/kg over 10 min, followed by continuous infusion of 0.2 1 µg/kg/h
Study: NCT04432623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benserazide Only Product
Description: Investigational drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benserazide Only Product
Description: Investigational drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benserazide Only Product
Description: Investigational drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benserazide Only Product
Description: Investigational drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benserazide Only Product
Description: Investigational drug
Study: NCT03332056

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Belladonna and Opium

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo suppository
Study: NCT02995200

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Accelerometer Based Feedback
Study: NCT03618069

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: CCI scanning (CTA, cardiac CT), and MRI scanning
Description: Scanning
Study: NCT02476981

Intervention type: DRUG
Group type: OTHER
Intervention: Dexmedetomidine
Description: Patients receiving dexmedetomidine were given that drug at 0.3-0.4 µg/kg over 10 min, followed by continuous infusion of 0.2 1 µg/kg/h

Intervention type: DRUG
Group type: OTHER
Intervention: Dexmedetomidine
Description: Patients receiving dexmedetomidine were given that drug at 0.3-0.4 µg/kg over 10 min, followed by continuous infusion of 0.2 1 µg/kg/h

Intervention type: DRUG
Group type: OTHER
Intervention: midazolam
Description: All patients were premedicated with midazolam 0.02 mg/kg before induction.

Intervention type: DRUG
Group type: OTHER
Intervention: propofol
Description: All patients in both groups received a bolus dose of propofol 0.3 mg/kg for sedative effect.
Study: NCT01786148

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: mobile phone application

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mobile phone application
Study: NCT01743183

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Threshold
Description: The load adjustment was done weekly by a single examiner.
Study: NCT02476981

Intervention type: DRUG
Group type: OTHER
Intervention: ephedrine
Description: Ephedrine 5 mg was injected when systolic blood pressure decreased below 90 mmHg
Study: NCT01397071

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Avocado
Description: Fresh Avocado

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Avocado
Description: Fresh Avocado
Study: NCT02353260

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound Hyperthermia
Description: treated with Therapeutic Ultrasound device on the 1st,3rd,5th,7th,9th day of each 21 day cycle
Study: NCT03773419

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Texting Intervention (T-WRITE)
Description: Computer-based intervention, guided by a virtual therapist, that involves repeated listening, reading and writing sentences using a cellular phone

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HandWriting Intervention (ORLA+WTG)
Description: Computer-based intervention, guided by a virtual therapist, that involves repeated listening, reading and writing sentences using pen and paper
Study: NCT01839409

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: vestibular stimulation
Description: Physical activity and vestibular stimulation will be used in order to improve circadian rhythms
Study: NCT02971839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-561

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IVA
Study: NCT02106806

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Zinc
Description: 35 mg of elemental zinc twice daily for 16 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc
Description: 35 mg of elemental zinc twice daily for 16 weeks

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: One capsule, twice daily for 16 weeks
Study: NCT04730687

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Traditional non surgical mechanical therapy
Description: Mechanical instrumentation in all groups was made with titanium Gracey curettes (8mm in diameter, Langer ½, item code: 7103, Kohler Medizintechnik, GmbH \& Co, Ltd, Stockach, Germany).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Diode laser assisted non-surgical mechancal therapy
Description: One week after mechanical treatment, a 940 nm diode laser (Ezlase®, Biolase Technology, Inc., San Clemente, CA) with a 300 µm diameter optical fiber tip applied approximately 1 mm above the most apical part of the peri-implant pocket, parallel to the implant surface (E3-9 mm).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Er, Cr: YSGG laser-assisted non-surgical mechanical therapy
Description: 1 week after mechanical treatment, 2780 nm Er, Cr: YSGG laser (Waterlase®, Biolase Technology, Inc., San Clemente, CA), short pulse '' H '' with 500 µm diameter fiberoptic periodontal tip (RFPT5-14 mm) mode has been applied.
Study: NCT00239590

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Testosterone undecanoate
Description: Licensed for androgen deficiency

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate
Description: Licensed for androgen deficiency
Study: NCT02106806

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One capsule, twice daily for 16 weeks
Study: NCT02772692

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Squatting pan
Description: Using squatting pans to replace standard-sized toilets in one group of the included constipation patients
Study: NCT02353260

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel,Cisplatin,Fluorouracil
Description: Squamous cell carcinoma of head and neck: Docetaxel(75mg/m²,d1/21d,2 cycles);Cisplatin(75mg/m²,d1/21d,2 cycles);Fluorouracil(750mg/m²/d,d1-5/21d, 2 cycles)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel,Cisplatin,Fluorouracil
Description: Squamous cell carcinoma of head and neck: Docetaxel(75mg/m²,d1/21d,2 cycles);Cisplatin(75mg/m²,d1/21d,2 cycles);Fluorouracil(750mg/m²/d,d1-5/21d, 2 cycles)
Study: NCT01470573

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biological replacement corneal surface
Description: the expanded tissue will be applied to patient to replace the damaged ocular surface
Study: NCT02085863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: laquinimod
Description: Oral laquinimod 0.6 mg capsules (with oral contraceptives tablets containing 30 μg ethinylestradiol and 150 μg levonorgestrel (Microgynon®)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: laquinimod
Description: Oral laquinimod 0.6 mg capsules (with oral contraceptives tablets containing 30 μg ethinylestradiol and 150 μg levonorgestrel (Microgynon®)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo (with oral contraceptives tablets containing 30 μg ethinylestradiol and 150 μg levonorgestrel (Microgynon®)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (with oral contraceptives tablets containing 30 μg ethinylestradiol and 150 μg levonorgestrel (Microgynon®)
Study: NCT02295865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-38518168 60 mg
Description: Two tablets of JNJ-38518168, 30 milligram (mg) each for a total of 60 mg, orally, once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-38518168 30 mg
Description: One tablet of JNJ-38518168, 30 mg, orally, once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-38518168 3 mg
Description: One tablet of JNJ-38518168, 3 mg, orally, once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching Placebo either 30 mg tablet or 3 mg tablet will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching Placebo either 30 mg tablet or 3 mg tablet will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching Placebo either 30 mg tablet or 3 mg tablet will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching Placebo either 30 mg tablet or 3 mg tablet will be administered orally.
Study: NCT03592017

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Long-wavelength autofluorescence imaging
Description: Long-wavelength autofluorescence imaging will be performed with a prototype confocal scanning laser (cSLO) ophthalmoscope which will be equipped with additional laser sources and a reference for quantification of the signal. The experimental long-wavelength laser sources will be integrated into a custom-modified Spectralis HRA cSLO from Heidelberg Engineering. The additional laser sources will operate with long wavelength which are less energetic compared to the conventional short-wavelength lasers used currently for routine autofluorescence imaging. All safety standards have been considered and the light exposure for all imaging modes is well below the exposure limits for Class 1 and Class1M laser products as defined in the standard IEC 60825-1, edition 3.0, 2014-5.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Long-wavelength autofluorescence imaging
Description: Long-wavelength autofluorescence imaging will be performed with a prototype confocal scanning laser (cSLO) ophthalmoscope which will be equipped with additional laser sources and a reference for quantification of the signal. The experimental long-wavelength laser sources will be integrated into a custom-modified Spectralis HRA cSLO from Heidelberg Engineering. The additional laser sources will operate with long wavelength which are less energetic compared to the conventional short-wavelength lasers used currently for routine autofluorescence imaging. All safety standards have been considered and the light exposure for all imaging modes is well below the exposure limits for Class 1 and Class1M laser products as defined in the standard IEC 60825-1, edition 3.0, 2014-5.
Study: NCT02989857

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AG-120
Description: Tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-120
Description: Tablet administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet administered orally
Study: NCT03955978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TSR-042
Description: -TSR-042 is administered intravenously via a 30-minute (-5-minute/+15-minute infusion window allowed) infusion

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Brachytherapy
Description: -This trial will include image-guided brachytherapy with three-dimensional (3-D) treatment planning and in cases where pelvic radiation is deemed appropriate by the treating radiation oncologist, external beam radiation therapy (EBRT) using intensity modulated radiation therapy (IMRT) technique.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endometrial biopsy
Description: -Prior to the start of treatment with TSR-042. If this biopsy yields insufficient tumor tissue, an archival sample may be requested, with Fraction 1 of brachytherapy, with Fraction 4 of brachytherapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood draw for immune response
Description: -Prior to the start of any treatment, at the time of brachytherapy fractions 1 and 4 (corresponding to endometrial biopsy), prior to fourth dose of TSR-042, 6 weeks after the completion of all protocol related therapy
Study: NCT05167708

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Micro-osteoperforation
Description: flapless small punctures in the bone at direction of tooth movement to accelerate the movement.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Micro-osteoperforation
Description: flapless small punctures in the bone at direction of tooth movement to accelerate the movement.